Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (2504)	10/8/1999 12:56:00 AM
From: John Metcalf	Read Replies (1) \| Respond to of 2742

Thanks for the work, Walter. ICAM-1 is a target of ICOS, which has completed Phase-II clinicals. Biotech Australia is still in pre-clins, and the research you reported is apparently in-vitro. Anti-sense is not at all a shoe-in, and other approaches may overtake ICOS. To demonstrate a superior drug-candidate, there would be animal trials ahead, an IND filing, and three phases of human trials. The possibilities for developing PAI-2 in this broad range of indications include partnering, and selling the rights. CIST has a lot of money relative to market cap, but not enough to make even a down payment on successful development. This is interesting as trade bait, but (hopefully) not a reason to continue to operate the company. As before, I think shareholder value will be best realized through a prompt sale of the whole entity.